• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优化 7-氮杂吲哚并喹啉拓扑异构酶 I 抑制剂的内酰胺侧链及其在癌细胞中的作用机制研究。

Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.

机构信息

Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and The Purdue Center for Cancer Research, Purdue University , West Lafayette, Indiana 47907, United States.

出版信息

J Med Chem. 2014 Feb 27;57(4):1289-98. doi: 10.1021/jm401471v. Epub 2014 Feb 6.

DOI:10.1021/jm401471v
PMID:24502276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3983387/
Abstract

Optimization of the lactam ω-aminoalkyl substituents in a series of 7-azaindenoisoquinolines resulted in new anticancer agents with improved Top1 inhibitory potencies and cancer cell cytotoxicities. The new compounds 14-17 and 19 exhibited mean graph midpoint cytotoxicity (GI50) values of 21-71 nM in the NCI panel of 60 human cancer cell cultures. Ternary 7-azaindenoisoquinoline-DNA-Top1 cleavage complexes that persist for up to 6 h were detected in HCT116 colon cancer cells. Ternary complexes containing 7-azaindenoisoquinolines were significantly more stable than those in which camptothecin was incorporated. DNA content distribution histograms showed S-phase block 3 h after drug removal. Drug-induced DNA damage in HCT116 cells was revealed by induction of the histone γ-H2AX marker. The 7-azaindenoisoquinolines were able to partially overcome resistance in several drug-resistant cell lines, and they were not substrates for the ABCB1 drug efflux transporter. Molecular modeling studies indicate that the 7-azaindenoisoquinolines intercalate at the DNA cleavage site in DNA-Top1 covalent complexes with the lactam side chain projecting into the major groove. Overall, the results indicate that the 7-azaindenoisoquinolines are promising anticancer agents that merit further development.

摘要

优化一系列 7-氮杂吲哚并异喹啉中的内酰胺 ω-氨基烷基取代基,得到了具有改进的 Top1 抑制活性和癌细胞细胞毒性的新型抗癌剂。新化合物 14-17 和 19 在 NCI panel 的 60 个人类癌细胞培养物中表现出 21-71 nM 的平均图形中点细胞毒性(GI50)值。在 HCT116 结肠癌细胞中检测到持续长达 6 小时的三元 7-氮杂吲哚并异喹啉-DNA-Top1 断裂复合物。含有 7-氮杂吲哚并异喹啉的三元复合物比包含喜树碱的三元复合物稳定得多。DNA 含量分布直方图显示药物去除后 3 小时出现 S 期阻滞。在 HCT116 细胞中,药物诱导的 DNA 损伤通过诱导组蛋白 γ-H2AX 标记物来揭示。7-氮杂吲哚并异喹啉能够部分克服几种耐药细胞系中的耐药性,并且它们不是 ABCB1 药物外排转运蛋白的底物。分子建模研究表明,7-氮杂吲哚并异喹啉在内酰胺侧链 projecting 进入大沟的情况下,在 DNA-Top1 共价复合物中在 DNA 切割部位插入。总体而言,结果表明 7-氮杂吲哚并异喹啉是有前途的抗癌剂,值得进一步开发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/5077926b8ae1/jm-2013-01471v_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/583befd8fa6e/jm-2013-01471v_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/a649fab76ae6/jm-2013-01471v_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/ed6236f2d1d3/jm-2013-01471v_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/9c2850160044/jm-2013-01471v_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/fbbd4da56a9c/jm-2013-01471v_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/d92cc0101865/jm-2013-01471v_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/d7470acf6004/jm-2013-01471v_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/10c69c4f61c4/jm-2013-01471v_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/5077926b8ae1/jm-2013-01471v_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/583befd8fa6e/jm-2013-01471v_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/a649fab76ae6/jm-2013-01471v_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/ed6236f2d1d3/jm-2013-01471v_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/9c2850160044/jm-2013-01471v_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/fbbd4da56a9c/jm-2013-01471v_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/d92cc0101865/jm-2013-01471v_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/d7470acf6004/jm-2013-01471v_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/10c69c4f61c4/jm-2013-01471v_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73d7/3983387/5077926b8ae1/jm-2013-01471v_0008.jpg

相似文献

1
Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.优化 7-氮杂吲哚并喹啉拓扑异构酶 I 抑制剂的内酰胺侧链及其在癌细胞中的作用机制研究。
J Med Chem. 2014 Feb 27;57(4):1289-98. doi: 10.1021/jm401471v. Epub 2014 Feb 6.
2
7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.7-氮杂吲哚并喹啉类化合物作为拓扑异构酶 I 抑制剂和潜在的抗癌剂。
J Med Chem. 2011 Sep 8;54(17):6106-16. doi: 10.1021/jm200719v. Epub 2011 Aug 8.
3
Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships.吖啶并异喹啉类作为拓扑异构酶 I 抑制剂和潜在的抗癌剂:构效关系的系统研究。
J Med Chem. 2012 Feb 23;55(4):1682-97. doi: 10.1021/jm201512x. Epub 2012 Feb 13.
4
Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.作为抑制拓扑异构酶I的强效细胞毒性抗癌剂的氯化和氟化7-氮杂二氢异喹啉的设计与合成
J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.
5
Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity.发现 4-烷氧基-2-芳基-6,7-二甲氧基喹啉类化合物作为一类新型拓扑异构酶 I 抑制剂,具有很强的体外抗癌活性。
Eur J Med Chem. 2021 Apr 5;215:113261. doi: 10.1016/j.ejmech.2021.113261. Epub 2021 Feb 9.
6
Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).人类拓扑异构酶1、酪氨酰-DNA磷酸二酯酶1(Tdp1)和酪氨酰-DNA磷酸二酯酶2(Tdp2)的首个三联抑制剂的合成与生物学评价
J Med Chem. 2017 Apr 27;60(8):3275-3288. doi: 10.1021/acs.jmedchem.6b01565. Epub 2017 Apr 18.
7
Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.氮杂 - A - 环茚并异喹啉拓扑异构酶I抑制剂的构效关系研究
J Med Chem. 2016 Apr 28;59(8):3840-53. doi: 10.1021/acs.jmedchem.6b00003. Epub 2016 Apr 12.
8
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.新型E环喜树碱酮类似物(S38809和S39625)是稳定、强效且具有选择性的拓扑异构酶I抑制剂,并非药物外排转运体的底物。
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3229-38. doi: 10.1158/1535-7163.MCT-07-0441.
9
Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.在内酰胺氮上带有多胺侧链的茚并异喹啉拓扑异构酶I抑制剂的设计、合成及生物学评价
J Med Chem. 2003 Dec 18;46(26):5712-24. doi: 10.1021/jm030313f.
10
Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.探索 DNA 拓扑异构酶 I 配体空间,寻找新型抗癌药物。
PLoS One. 2011;6(9):e25150. doi: 10.1371/journal.pone.0025150. Epub 2011 Sep 22.

引用本文的文献

1
Design, Synthesis and Bioactive Evaluation of Topo I/ Dual Inhibitors to Inhibit Oral Cancer via Regulating the PI3K/AKT/NF-κB Signaling Pathway.通过调节PI3K/AKT/NF-κB信号通路抑制口腔癌的拓扑异构酶I/双重抑制剂的设计、合成及生物活性评价
Molecules. 2025 Feb 14;30(4):894. doi: 10.3390/molecules30040894.
2
Design, Synthesis, and Investigation of the Pharmacokinetics and Anticancer Activities of Indenoisoquinoline Derivatives That Stabilize the G-Quadruplex in the Promoter and Inhibit Topoisomerase I.设计、合成及吲哚异喹啉衍生物的药代动力学和抗癌活性研究,该衍生物能稳定启动子中的 G-四链体并抑制拓扑异构酶 I。
J Med Chem. 2024 May 9;67(9):7006-7032. doi: 10.1021/acs.jmedchem.3c02303. Epub 2024 Apr 26.
3

本文引用的文献

1
Topoisomerase inhibitors as anticancer agents: a patent update.拓扑异构酶抑制剂作为抗癌药物:专利更新。
Expert Opin Ther Pat. 2013 Aug;23(8):1033-56. doi: 10.1517/13543776.2013.790958. Epub 2013 Apr 23.
2
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.CellMiner:一套基于网络的基因组学和药理学工具套件,用于探索 NCI-60 细胞系集中的转录组和药物模式。
Cancer Res. 2012 Jul 15;72(14):3499-511. doi: 10.1158/0008-5472.CAN-12-1370.
3
Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships.
Rh-Catalyzed Cascade C-H Activation/Annulation of -Hydroxybenzamides and Propargylic Acetates for Modular Access to Isoquinolones.
Rh 催化的 -羟基苯甲酰胺和炔丙基乙酸酯的级联 C-H 活化/环化反应用于构建异喹啉酮的模块化方法。
Molecules. 2022 Dec 5;27(23):8553. doi: 10.3390/molecules27238553.
4
Indenoisoquinoline Topoisomerase Inhibitors Strongly Bind and Stabilize the Promoter G-Quadruplex and Downregulate .吲哚异喹啉拓扑异构酶抑制剂强烈结合并稳定启动子 G-四链体,下调.
J Am Chem Soc. 2019 Jul 17;141(28):11059-11070. doi: 10.1021/jacs.9b02679. Epub 2019 Jul 8.
5
Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.发现、合成及氧亚乙基啶衍生物作为 DNA 拓扑异构酶 IB(TOP1)和酪氨酰 DNA 磷酸二酯酶 1(TDP1)双重抑制剂及潜在抗肿瘤剂的评价。
J Med Chem. 2018 Nov 21;61(22):9908-9930. doi: 10.1021/acs.jmedchem.8b00639. Epub 2018 Oct 31.
6
Synthesis of indolo[4,3-]phenanthridine-6,11(2,12)-diones using the Schiff base-homophthalic anhydride cyclization reaction.利用席夫碱-高邻苯二甲酸酐环化反应合成吲哚并[4,3-]菲啶-6,11(2,12)-二酮
Synth Commun. 2016;46(23):1902-1908. doi: 10.1080/00397911.2016.1232409. Epub 2016 Sep 16.
7
Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.作为抑制拓扑异构酶I的强效细胞毒性抗癌剂的氯化和氟化7-氮杂二氢异喹啉的设计与合成
J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.
8
Interlinked DNA nano-circles for measuring topoisomerase II activity at the level of single decatenation events.用于在单个解连环事件水平上测量拓扑异构酶II活性的相互连接的DNA纳米环。
Nucleic Acids Res. 2017 Jul 27;45(13):7855-7869. doi: 10.1093/nar/gkx480.
9
Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).人类拓扑异构酶1、酪氨酰-DNA磷酸二酯酶1(Tdp1)和酪氨酰-DNA磷酸二酯酶2(Tdp2)的首个三联抑制剂的合成与生物学评价
J Med Chem. 2017 Apr 27;60(8):3275-3288. doi: 10.1021/acs.jmedchem.6b01565. Epub 2017 Apr 18.
10
Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).与实验性抗癌药物吲哚托康(LMP400)相关的潜在前药的设计、合成及生物学评价
J Med Chem. 2016 May 26;59(10):4890-9. doi: 10.1021/acs.jmedchem.6b00220. Epub 2016 Apr 20.
吖啶并异喹啉类作为拓扑异构酶 I 抑制剂和潜在的抗癌剂:构效关系的系统研究。
J Med Chem. 2012 Feb 23;55(4):1682-97. doi: 10.1021/jm201512x. Epub 2012 Feb 13.
4
Interfacial inhibitors: targeting macromolecular complexes.界面抑制剂:靶向大分子复合物。
Nat Rev Drug Discov. 2011 Dec 16;11(1):25-36. doi: 10.1038/nrd3404.
5
7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.7-氮杂吲哚并喹啉类化合物作为拓扑异构酶 I 抑制剂和潜在的抗癌剂。
J Med Chem. 2011 Sep 8;54(17):6106-16. doi: 10.1021/jm200719v. Epub 2011 Aug 8.
6
Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.新型非喜树碱拓扑异构酶 I 抑制剂 Genz-644282 的分子和细胞药理学。
Mol Cancer Ther. 2011 Aug;10(8):1490-9. doi: 10.1158/1535-7163.MCT-10-1043. Epub 2011 Jun 2.
7
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.聚(ADP-核糖)聚合酶和 XPF-ERCC1 参与修复哺乳动物细胞中拓扑异构酶 I 诱导的 DNA 损伤的不同途径。
Nucleic Acids Res. 2011 May;39(9):3607-20. doi: 10.1093/nar/gkq1304. Epub 2011 Jan 11.
8
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.吲哚并异喹啉类非喜树碱拓扑异构酶 I 抑制剂:最新研究进展及展望。
Mol Cancer Ther. 2009 May;8(5):1008-14. doi: 10.1158/1535-7163.MCT-08-0706. Epub 2009 Apr 21.
9
DNA cleavage assay for the identification of topoisomerase I inhibitors.用于鉴定拓扑异构酶I抑制剂的DNA切割试验
Nat Protoc. 2008;3(11):1736-50. doi: 10.1038/nprot.2008.174.
10
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.新型茚并异喹啉类化合物NSC 725776和NSC 724998可产生持续的拓扑异构酶I切割复合物并克服多药耐药性。
Cancer Res. 2007 Nov 1;67(21):10397-405. doi: 10.1158/0008-5472.CAN-07-0938.